theory clinical_64_2
imports Main

begin

typedecl entity
typedecl event

consts
  KinaseInhibitor :: "entity ⇒ bool"
  Mutations :: "entity ⇒ bool"
  PI3KAKTPathway :: "entity ⇒ bool"
  Target :: "event ⇒ bool"
  Agent :: "event ⇒ entity ⇒ bool"
  PatientEvent :: "event ⇒ entity ⇒ bool"
  In :: "entity ⇒ entity ⇒ bool"
  Inhibit :: "event ⇒ bool"
  Proliferation :: "entity ⇒ bool"
  Survival :: "entity ⇒ bool"
  Treatment :: "entity ⇒ bool"
  AlpelisibFulvestrant :: "entity ⇒ bool"
  Beneficial :: "entity ⇒ bool"
  Patient :: "entity ⇒ bool"
  PIK3CAMutated :: "entity ⇒ bool"
  HRPositive :: "entity ⇒ bool"
  HER2Negative :: "entity ⇒ bool"
  AdvancedBreastCancer :: "entity ⇒ bool"
  EndocrineTherapy :: "entity ⇒ bool"
  Received :: "event ⇒ bool"
  Previously :: "event ⇒ bool"
  PIK3CAMutation :: "entity ⇒ bool"
  Prolong :: "event ⇒ bool"
  ProgressionFreeSurvival :: "entity ⇒ bool"
  LessSensitive :: "entity ⇒ entity ⇒ bool"
  Chemotherapy :: "entity ⇒ bool"
  Benefit :: "event ⇒ bool"
  From :: "event ⇒ entity ⇒ bool"

(* Explanation 1: Using a kinase inhibitor may target mutations in the PI3K/AKT pathway and inhibit proliferation and survival. *)
axiomatization where
  explanation_1: "∃x y z e1 e2. KinaseInhibitor x ∧ Mutations y ∧ PI3KAKTPathway z ∧ Target e1 ∧ Agent e1 x ∧ PatientEvent e1 y ∧ In y z ∧ Inhibit e2 ∧ Agent e2 x ∧ Proliferation y ∧ Survival y"

(* Explanation 2: Treatment with alpelisib–fulvestrant is beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously, as it targets the PIK3CA mutation and prolongs progression-free survival. *)
axiomatization where
  explanation_2: "∃x y z w e1 e2 e3. Treatment x ∧ AlpelisibFulvestrant x ∧ Beneficial x ∧ Patient y ∧ PIK3CAMutated y ∧ HRPositive y ∧ HER2Negative y ∧ AdvancedBreastCancer y ∧ EndocrineTherapy z ∧ Received e1 ∧ Agent e1 y ∧ PatientEvent e1 z ∧ Previously e1 ∧ PIK3CAMutation w ∧ Target e2 ∧ Agent e2 x ∧ PatientEvent e2 w ∧ Prolong e3 ∧ Agent e3 x ∧ ProgressionFreeSurvival w"

(* Explanation 3: Patient is likely less sensitive to chemotherapy. *)
axiomatization where
  explanation_3: "∀x y. Patient x ∧ Chemotherapy y ⟶ LessSensitive x y"

theorem hypothesis:
  assumes asm: "Patient x ∧ EndocrineTherapy y ∧ Received e1 ∧ Agent e1 x ∧ PatientEvent e1 y ∧ Previously e1"
  (* Hypothesis: If patient has previously received endocrine therapy, they may benefit from treatment with alpelisib-fulvestrant to target PIK3CA mutation *)
  shows "∀x y z e1 e2. (Patient x ∧ EndocrineTherapy y ∧ Received e1 ∧ Agent e1 x ∧ PatientEvent e1 y ∧ Previously e1) ⟶ (Benefit e2 ∧ Agent e2 x ∧ Treatment z ∧ From e2 z ∧ Target e2 ∧ PIK3CAMutation z)"
proof -
  (* From the premise, we have the known information about the patient and their previous endocrine therapy. *)
  from asm have "Patient x ∧ EndocrineTherapy y ∧ Received e1 ∧ Agent e1 x ∧ PatientEvent e1 y ∧ Previously e1" by blast
  (* Explanation 2 provides that treatment with alpelisib–fulvestrant is beneficial for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously. *)
  (* This implies that such patients may benefit from treatment with alpelisib-fulvestrant to target the PIK3CA mutation. *)
  (* We can use the logical relation Implies(D, And(E, F, G)) to infer the benefit and targeting of PIK3CA mutation. *)
  then have "Benefit e2 ∧ Agent e2 x ∧ Treatment z ∧ From e2 z ∧ Target e2 ∧ PIK3CAMutation z" sledgehammer
  then show ?thesis <ATP>
qed

end
